The dopamine theory of addiction: 40 years of highs and lowsDavid Nutt, Paul Stokes|Nature reviews. Neuroscience|2015Cited by 653
Amphetamine, past and present – a pharmacological and clinical perspectiveDavid J. Heal, David Nutt, Sharon L. Smith et al.|Journal of Psychopharmacology|2013Cited by 614
Estimating the Harms of Nicotine-Containing Products Using the MCDA ApproachDavid Nutt, David Sweanor, Lawrence D. Phillips et al.|European Addiction Research|2014Cited by 442
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for PsychopharmacologyBlanca Bolea-Alamañac, David Nutt, Marios Adamou et al.|Journal of Psychopharmacology|2014Cited by 284
Benzodiazepines: Risks and benefits. A reconsiderationDavid S. Baldwin, Sue Wilson, Katherine J. Aitchison et al.|Journal of Psychopharmacology|2013Cited by 236